

Cover Story
Conversation with The Cancer Letter
By Matthew Bin Han Ong
Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?
By Alexandria Carolan
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - $180M in NCI grants have been terminated by Trump administration, systematic review finds